Cerecor Inc (CERC) Short Interest Down 33.8% in January

Cerecor Inc (NASDAQ:CERC) was the target of a large decrease in short interest in January. As of January 12th, there was short interest totalling 777,488 shares, a decrease of 33.8% from the December 29th total of 1,174,319 shares. Approximately 4.1% of the company’s stock are short sold. Based on an average daily volume of 493,309 shares, the short-interest ratio is presently 1.6 days.

Shares of Cerecor (NASDAQ:CERC) opened at $3.47 on Monday. Cerecor has a 52 week low of $0.34 and a 52 week high of $4.25. The stock has a market cap of $90.41 and a P/E ratio of 9.38.

Cerecor (NASDAQ:CERC) last posted its earnings results on Monday, November 6th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.76. Cerecor had a net margin of 51.71% and a return on equity of 212.90%. analysts expect that Cerecor will post 0.83 EPS for the current year.

In related news, major shareholder Armistice Capital Master Fund bought 45,200 shares of Cerecor stock in a transaction dated Friday, November 24th. The stock was purchased at an average cost of $1.20 per share, with a total value of $54,240.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Armistice Capital, Llc bought 35,200 shares of Cerecor stock in a transaction dated Wednesday, November 22nd. The shares were bought at an average cost of $1.20 per share, with a total value of $42,240.00. The disclosure for this purchase can be found here. Insiders acquired a total of 90,685 shares of company stock valued at $108,984 over the last ninety days. 10.70% of the stock is currently owned by insiders.

A hedge fund recently bought a new stake in Cerecor stock. Acadian Asset Management LLC acquired a new stake in shares of Cerecor Inc (NASDAQ:CERC) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 60,719 shares of the company’s stock, valued at approximately $194,000. Acadian Asset Management LLC owned approximately 0.23% of Cerecor as of its most recent filing with the SEC. 64.03% of the stock is owned by institutional investors.

CERC has been the topic of several recent analyst reports. ValuEngine upgraded shares of Cerecor from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 7th. TheStreet upgraded shares of Cerecor from an “e+” rating to a “c-” rating in a research note on Wednesday, November 8th.

TRADEMARK VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/29/cerecor-inc-cerc-short-interest-down-33-8-in-january.html.

About Cerecor

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply